TY - JOUR
T1 - Pharmacogenomic associations of adverse drug reactions in asthma
T2 - systematic review and research prioritisation
AU - King, Charlotte
AU - McKenna, Amanda
AU - Farzan, Niloufar
AU - Vijverberg, Susanne J
AU - van der Schee, Marc P
AU - Maitland-van der Zee, Anke H
AU - Arianto, Lambang
AU - Bisgaard, Hans
AU - BØnnelykke, Klaus
AU - Berce, Vojko
AU - Potočnik, Uroš
AU - Repnik, Katja
AU - Carleton, Bruce
AU - Daley, Denise
AU - Chew, Fook Tim
AU - Chiang, Wen Chin
AU - Sio, Yang Yie
AU - Cloutier, Michelle M
AU - Den Dekker, Herman T
AU - Duijts, Liesbeth
AU - de Jongste, Johan C
AU - Dijk, F Nicole
AU - Koppelman, Gerard H
AU - Flores, Carlos
AU - Hernandez-Pacheco, Natalia
AU - Pino-Yanes, Maria
AU - Mukhopadhyay, Somnath
AU - Basu, Kaninika
AU - Bignell, Lauren
AU - Tantisira, Kelan G
AU - Turner, Steve
AU - Verhamme, Katia M
AU - Francis, Ben
AU - Pirmohamed, Munir
AU - Sinha, Ian
AU - Hawcutt, Daniel B
PY - 2020/10
Y1 - 2020/10
N2 - A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.
AB - A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.
UR - http://www.scopus.com/inward/record.url?scp=85078235110&partnerID=8YFLogxK
U2 - 10.1038/s41397-019-0140-y
DO - 10.1038/s41397-019-0140-y
M3 - Review
C2 - 31949291
SN - 1470-269X
VL - 20
SP - 621
EP - 628
JO - The pharmacogenomics journal
JF - The pharmacogenomics journal
IS - 5
ER -